AbbVie reached a deal with the Trump administration on drug prices in exchange for being exempted from tariffs and future ...

The first two days of the J.P. Morgan Healthcare Conference are in the books, and attendees are now pushing through to finish ...

Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...

Tremfya and Icotide are touted as key growth drivers in J&J’s strongly performing innovative medicines business.

Look into AbbVie's strategy a company built around its blockbuster Humira, now diversifying its pipeline after the patent ...

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The oncology segment alone is expected to generate $232 billion in sales this year.

But a health care technology company says cost concerns are prompting Americans to abandon nearly a hundred million ...

Both Skyrizi and its cousin Rinvoq have landed in the annual top three, in varying positions, since 2022. That was once again the case in 2025, when Skyrizi retained its place at the top and Rinvoq ...